Table 1.
Clinical data in the patients who had received cord blood transplantation (CBT) and unrelated bone marrow transplantation (UBMT)
| CBT |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Disease | Disease status | Age at allo-HCT | Gender | Source | CMV status | Conditioning | GVHD prophylaxis | Duration (years post allo-HCT) |
| AML | NC | 57 | F | CB | + | FLU+Mel+CA+TBI | CsA+sMTX | 2.8 |
| ATLL | CR1 | 57 | M | CB | + | FLU+Mel+TBI | CsA+sMTX | 3.4 |
| Ph+ALL | CR2 | 48 | M | CB | + | FLU+BU4+TBI | CsA+sMTX | 2.4 |
| DLBCL | CR2 | 51 | F | CB | + | FLU+Mel+TBI | CsA+sMTX | 2.4 |
| CMMoL | NC | 40 | M | CB | + | CY+TBI | CsA+sMTX | 3.9 |
| Ph+ALL | CR2 | 44 | M | CB | + | CY+TBI | CsA+sMTX | 6.1 |
| FL | NC | 56 | M | CB | + | FLU+Mel+TBI | CsA+sMTX | 7.9 |
| ALL | CR1 | 32 | F | CB | + | CY+TBI | CsA+sMTX | 9.5 |
| FL | CR3 | 51 | M | CB | + | FLU+Mel+TBI | CsA+sMTX | 5.5 |
| ALL | CR1 | 41 | M | CB | + | FLU+Mel+TBI | CsA+sMTX | 4.0 |
| AML | CR1 | 45 | M | CB | + | CY+AraC+TBI | CsA+sMTX | 7.3 |
| AML | CR2 | 45 | F | CB | + | FLU+BU+TBI | CsA+sMTX | 3.0 |
| Ph+ALL | CR1 | 39 | F | CB | - | CY+TBI | CsA+sMTX | 10.8 |
| AML | CR2 | 44 | F | CB | + | CY+TBI | CsA+sMTX | 7.1 |
| PTCL | NC | 33 | M | CB | + | CY+TBI | CsA+sMTX | 7.6 |
| AML | CR1 | 52 | F | CB | + | FLU+Mel+TBI | CsA+sMTX | 3.5 |
| AML | CR1 | 38 | F | CB | + | CY+TBI | CsA+sMTX | 2.1 |
| CML | CP1 | 24 | M | CB | + | CY+TBI | CsA+sMTX | 13.1 |
| ATLL | CR1 | 41 | F | CB | + | FLU+Mel+TBI | CsA+sMTX | 3.1 |
| MDS | RA | 62 | M | CB | + | FLU+CA+Mel+TBI | CsA+sMTX | 6.3 |
| Ph+ALL | CR1 | 63 | M | CB | + | FLU+Mel+TBI | CsA+sMTX | 6.2 |
| UBMT | ||||||||
| AML | CR1 | 25 | F | uBM | + | CY+TBI | CsA+sMTX | 8.8 |
| MDS | RAEB | 54 | M | uBM | + | CY+TBI | CsA+sMTX | 7.8 |
| AML | CR1 | 34 | M | uBM | + | CY+TBI | CsA+sMTX | 3.4 |
| ALCL | CR2 | 56 | M | uBM | + | FLU+Mel+TBI | CsA+sMTX | 4.3 |
| AML | CR2 | 48 | F | uBM | - | FLU+BU4+TBI | CsA+sMTX | 5.0 |
| MM | sCR | 39 | F | uBM | - | FLU+Mel+TBI | CsA+sMTX | 2.1 |
| DLBCL | CR2 | 44 | F | uBM | + | FLU+BU2 | CsA+sMTX | 6.8 |
| FL | CR2 | 46 | F | uBM | + | FLU+Mel | CsA+sMTX | 9.3 |
| MDS | RAEB2 | 26 | M | uBM | - | CY+TBI | CsA+sMTX | 10.3 |
| AML | CR1 | 26 | F | uBM | + | CY+TBI | CsA+sMTX | 13.6 |
| MDS | RAEB | 38 | M | uBM | + | CY+TBI | CsA+sMTX | 6.2 |
| AML | CR1 | 38 | F | uBM | + | CY+TBI | CsA+sMTX | 8.0 |
| PNH/AA | 39 | F | uBM | + | CY+FLU+ATG | CsA+sMTX | 3.8 | |
| AML | CR1 | 49 | M | uBM | + | CY+TBI | CsA+sMTX | 10.2 |
| MDS | RAEB2 | 29 | M | uBM | + | CY+TBI | CsA+sMTX | 8.0 |
| CML | BC | 35 | F | uBM | + | CY+TBI | CsA+sMTX | 11.7 |
| NHL | CR2 | 32 | M | uBM | + | CY+TBI | CsA+sMTX | 14.1 |
| CML | CR2 | 38 | M | uBM | + | CY+TBI | CsA+sMTX | 6.6 |
| AML | CR2 | 20 | F | uBM | + | FLU+BU2+TBI | Tac+sMTX | 2.2 |
| DLBCL | NC | 48 | F | uBM | + | FLU+BU2+TBI | CsA+sMTX | 2.2 |
Allo-HCT; allogeneic hematopoietic cell transplantation, CMV; cytomegalovirus, GVHD; graft-versus-host disease, AML; acute myelogenous leukemia, ATLL; adult T cell leukemia/lymphoma, Ph+ALL; Philadelphia chromosome positive acute lymphoblastic leukemia, DLBCL; diffuse large B cell lymphoma, CMMoL; chronic myelomomocytic leukemia, FL; follicular lymphoma, ALL; acute lymphoblastic leukemia, PTCL; peripheral T cell lymphoma, CML; chronic myelogenous leukemia, MDS; myelodysplastic syndrome, ALCL; anaplastic large cell lymphoma, MM; multiple myeloma, PNH/AA; paroxysmal nocturnal hematuria/aplastic anemia, NHL; non-Hodgkin lymphoma, NC; non-complete remission, CR1; first complete remission, CR2; second complete remission, CR3; third complete remission, RA; refractory anemia, RAEB; refractory anemia with excess blast, sCR; stringent complete remission, BC; blastic crisis, CB; cord blood, UBMT; unrelated bone marrow transplantation, FLU; fludarabine, Mel; melphalan, CA; cytosine-arabinocyde, TBI; total body irradiation, BU; buslfan, CY; cyclophosphamide, CsA; cyclosporine A, sMTX; short-term methotrexate.